The SIX1-EYA transcriptional complex as a therapeutic target in cancer

Bibliography

• Kumar JP. The sine oculis homeobox (SIX) family of transcription factors as regulators of development and disease. Cell Mol Life Sci 2009;66(4):565-83
   PubMed Web of Science ®Google Scholar
• Xu PX. The EYA-SO/SIX complex in development and disease. Pediatr Nephrol 2012;28(6):843-54
   Google Scholar
• Ford HL, Kabingu EN, Bump EA, et al. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc Natl Acad Sci USA 1998;95(21):12608-13
   Google Scholar
• Li X, Oghi KA, Zhang J, et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 2003;426(6964):247-54
   PubMed Web of Science ®Google Scholar
• Coletta RD, Christensen K, Reichenberger KJ, et al. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci USA 2004;101(17):6478-83
   PubMed Web of Science ®Google Scholar
• Li X, Perissi V, Liu F, et al. Tissue-specific regulation of retinal and pituitary precursor cell proliferation. Science 2002;297(5584):1180-3
   PubMed Web of Science ®Google Scholar
• Del Bene F, Tessmar-Raible K, Wittbrodt J. Direct interaction of geminin and Six3 in eye development. Nature 2004;427(6976):745-9
   Google Scholar
• El-Hashash AH, Al Alam D, Turcatel G, et al. Six1 transcription factor is critical for coordination of epithelial, mesenchymal and vascular morphogenesis in the mammalian lung. Dev Biol 2011;353(2):242-58
   Google Scholar
• Self M, Lagutin OV, Bowling B, et al. Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J 2006;25(21):5214-28
   Google Scholar
• Kobayashi H, Kawakami K, Asashima M, et al. Six1 and Six4 are essential for Gdnf expression in the metanephric mesenchyme and ureteric bud formation, while Six1 deficiency alone causes mesonephric-tubule defects. Mech Dev 2007;124(4):290-303
   Google Scholar
• Abdelhak S, Kalatzis V, Heilig R, et al. A human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family. Nat Genet 1997;15(2):157-64
   Google Scholar
• Hoskins BE, Cramer CH, Silvius D, et al. Transcription factor SIX5 is mutated in patients with branchio-oto-renal syndrome. Am J Hum Genet 2007;80(4):800-4
   Google Scholar
• Laclef C, Hamard G, Demignon J, et al. Altered myogenesis in Six1-deficient mice. Development 2003;130(10):2239-52
   Google Scholar
• Laclef C, Souil E, Demignon J, et al. Thymus, kidney and craniofacial abnormalities in Six1 deficient mice. Mech Dev 2003;120(6):669-79
   Google Scholar
• Xu PX, Zheng W, Huang L, et al. Six1 is required for the early organogenesis of mammalian kidney. Development 2003;130(14):3085-94
   Google Scholar
• Zheng W, Huang L, Wei ZB, et al. The role of Six1 in mammalian auditory system development. Development 2003;130(17):3989-4000
   Google Scholar
• Christensen KL, Patrick AN, McCoy EL, et al. The six family of homeobox genes in development and cancer. Adv Cancer Res 2008;101:93-126
   PubMed Web of Science ®Google Scholar
• Kawakami K, Sato S, Ozaki H, et al. Six family genes – structure and function as transcription factors and their roles in development. Bioessays 2000;22(7):616-26
   PubMed Web of Science ®Google Scholar
• Patrick AN, Cabrera JH, Smith AL, et al. Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome. Nat Struct Mol Biol 2013;20(4):447-53
   Google Scholar
• Kawakami K, Ohto H, Ikeda K, et al. Structure, function and expression of a murine homeobox protein AREC3, a homologue of Drosophila sine oculis gene product, and implication in development. Nucleic Acids Res 1996;24(2):303-10
   Google Scholar
• Brodbeck S, Besenbeck B, Englert C. The transcription factor Six2 activates expression of the Gdnf gene as well as its own promoter. Mech Dev 2004;121(10):1211-22
   Google Scholar
• Rebay I, Silver SJ, Tootle TL. New vision from Eyes absent: transcription factors as enzymes. Trends Genet 2005;21(3):163-71
   Google Scholar
• Ohto H, Kamada S, Tago K, et al. Cooperation of six and eya in activation of their target genes through nuclear translocation of Eya. Mol Cell Biol 1999;19(10):6815-24
   PubMedGoogle Scholar
• Xu PX, Cheng J, Epstein JA, et al. Mouse Eya genes are expressed during limb tendon development and encode a transcriptional activation function. Proc Natl Acad Sci USA 1997;94(22):11974-9
   Google Scholar
• Okabe Y, Sano T, Nagata S. Regulation of the innate immune response by threonine-phosphatase of Eyes absent. Nature 2009;460(7254):520-4
   Google Scholar
• Sano T, Nagata S. Characterization of the threonine-phosphatase of mouse eyes absent 3. FEBS Lett 2011;585(17):2714-19
   Google Scholar
• Tadjuidje E, Hegde RS. The Eyes Absent proteins in development and disease. Cell Mol Life Sci 2013;70(11):1897-913
   PubMed Web of Science ®Google Scholar
• Tootle TL, Silver SJ, Davies EL, et al. The transcription factor Eyes absent is a protein tyrosine phosphatase. Nature 2003;426(6964):299-302
   Google Scholar
• Rayapureddi JP, Kattamuri C, Steinmetz BD, et al. Eyes absent represents a class of protein tyrosine phosphatases. Nature 2003;426(6964):295-8
   Google Scholar
• Cook PJ, Ju BG, Telese F, et al. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 2009;458(7238):591-6
   PubMed Web of Science ®Google Scholar
• Krishnan N, Jeong DG, Jung SK, et al. Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent. J Biol Chem 2009;284(24):16066-70
   PubMed Web of Science ®Google Scholar
• Yuan B, Cheng L, Chiang HC, et al. A phosphotyrosine switch determines the antitumor activity of ERbeta. J Clin Invest 2014;124(8):3378-90
   Google Scholar
• Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011;11(8):597-608
   PubMed Web of Science ®Google Scholar
• Nica G, Herzog W, Sonntag C, et al. Eya1 is required for lineage-specific differentiation, but not for cell survival in the zebrafish adenohypophysis. Dev Biol 2006;292(1):189-204
   Google Scholar
• Xu PX, Adams J, Peters H, et al. Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia. Nat Genet 1999;23(1):113-17
   Google Scholar
• Zou D, Silvius D, Fritzsch B, et al. Eya1 and Six1 are essential for early steps of sensory neurogenesis in mammalian cranial placodes. Development 2004;131(22):5561-72
   Google Scholar
• Brugmann SA, Pandur PD, Kenyon KL, et al. Six1 promotes a placodal fate within the lateral neurogenic ectoderm by functioning as both a transcriptional activator and repressor. Development 2004;131(23):5871-81
   Google Scholar
• Ruf RG, Xu PX, Silvius D, et al. SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes. Proc Natl Acad Sci USA 2004;101(21):8090-5
   Google Scholar
• Kozlowski DJ, Whitfield TT, Hukriede NA, et al. The zebrafish dog-eared mutation disrupts eya1, a gene required for cell survival and differentiation in the inner ear and lateral line. Dev Biol 2005;277(1):27-41
   Google Scholar
• Bricaud O, Collazo A. The transcription factor six1 inhibits neuronal and promotes hair cell fate in the developing zebrafish (Danio rerio) inner ear. J Neurosci 2006;26(41):10438-51
   Google Scholar
• Li Y, Manaligod JM, Weeks DL. EYA1 mutations associated with the branchio-oto-renal syndrome result in defective otic development in Xenopus laevis. Biol Cell 2010;102(5):277-92
   Google Scholar
• Zou D, Silvius D, Rodrigo-Blomqvist S, et al. Eya1 regulates the growth of otic epithelium and interacts with Pax2 during the development of all sensory areas in the inner ear. Dev Biol 2006;298(2):430-41
   Google Scholar
• Song MH, Kwon TJ, Kim HR, et al. Mutational analysis of EYA1, SIX1 and SIX5 genes and strategies for management of hearing loss in patients with BOR/BO syndrome. PLoS One 2013;8:6):e67236
   Google Scholar
• Azuma N, Hirakiyama A, Inoue T, et al. Mutations of a human homologue of the Drosophila eyes absent gene (EYA1) detected in patients with congenital cataracts and ocular anterior segment anomalies. Hum Mol Genet 2000;9(3):363-6
   Google Scholar
• Orten DJ, Fischer SM, Sorensen JL, et al. Branchio-oto-renal syndrome (BOR): novel mutations in the EYA1 gene, and a review of the mutational genetics of BOR. Hum Mutat 2008;29(4):537-44
   Google Scholar
• Patrick AN, Schiemann BJ, Yang K, et al. Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutations. J Biol Chem 2009;284(31):20781-90
   Google Scholar
• Buller C, Xu X, Marquis V, et al. Molecular effects of Eya1 domain mutations causing organ defects in BOR syndrome. Hum Mol Genet 2001;10(24):2775-81
   Google Scholar
• Rayapureddi JP, Hegde RS. Branchio-oto-renal syndrome associated mutations in Eyes Absent 1 result in loss of phosphatase activity. FEBS Lett 2006;580(16):3853-9
   Google Scholar
• Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2(10):777-85
   PubMed Web of Science ®Google Scholar
• Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004;10(2):175-81
   Google Scholar
• Micalizzi DS, Christensen KL, Jedlicka P, et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 2009;119(9):2678-90
   Google Scholar
• Ng KT, Man K, Sun CK, et al. Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. Br J Cancer 2006;95(8):1050-5
   PubMed Web of Science ®Google Scholar
• Behbakht K, Qamar L, Aldridge CS, et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007;67(7):3036-42
   Google Scholar
• Mimae T, Okada M, Hagiyama M, et al. Upregulation of notch2 and six1 is associated with progression of early-stage lung adenocarcinoma and a more aggressive phenotype at advanced stages. Clin Cancer Res 2012;18(4):945-55
   Google Scholar
• Zheng XH, Liang PH, Guo JX, et al. Expression and clinical implications of homeobox gene Six1 in cervical cancer cell lines and cervical epithelial tissues. Int J Gynecol Cancer 2010;20(9):1587-92
   Google Scholar
• Li Z, Tian T, Lv F, et al. Six1 promotes proliferation of pancreatic cancer cells via upregulation of cyclin D1 expression. PLoS One 2013;8(3):e59203
   PubMed Web of Science ®Google Scholar
• Yu Y, Davicioni E, Triche TJ, et al. The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res 2006;66(4):1982-9
   Google Scholar
• Iwanaga R, Wang CA, Micalizzi DS, et al. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res 2012;14(4):R100
   Google Scholar
• McCoy EL, Iwanaga R, Jedlicka P, et al. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest 2009;119(9):2663-77
   Google Scholar
• Wang CA, Jedlicka P, Patrick AN, et al. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J Clin Invest 2012;122(5):1895-906
   PubMed Web of Science ®Google Scholar
• Ng KT, Lee TK, Cheng Q, et al. Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1. Int J Cancer 2010;127(4):859-72
   Google Scholar
• Micalizzi DS, Wang CA, Farabaugh SM, et al. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res 2010;70(24):10371-80
   PubMed Web of Science ®Google Scholar
• Coletta RD, Christensen KL, Micalizzi DS, et al. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Res 2008;68(7):2204-13
   PubMed Web of Science ®Google Scholar
• Imam JS, Buddavarapu K, Lee-Chang JS, et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 2010;29(35):4971-9
   PubMed Web of Science ®Google Scholar
• Hua L, Fan L, Aichun W, et al. Inhibition of Six1 promotes apoptosis, suppresses proliferation, and migration of osteosarcoma cells. Tumour Biol 2014;35(3):1925-31
   Google Scholar
• Li Z, Tian T, Hu X, et al. Six1 mediates resistance to paclitaxel in breast cancer cells. Biochem Biophys Res Commun 2013;441(3):538-43
   PubMed Web of Science ®Google Scholar
• Tan J, Zhang C, Qian J. Expression and significance of Six1 and Ezrin in cervical cancer tissue. Tumour Biol 2011;32(6):1241-7
   Google Scholar
• Ono H, Imoto I, Kozaki K, et al. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. Oncogene 2012;31(47):4923-34
   PubMed Web of Science ®Google Scholar
• Zhao H, Xu Z, Qin H, et al. miR-30b regulates migration and invasion of human colorectal cancer via SIX1. Biochem J 2014;460(1):117-25
   PubMed Web of Science ®Google Scholar
• Li Z, Tian T, Hu X, et al. Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion. Int J Clin Exp Pathol 2014;7(2):631-9
   Google Scholar
• Reichenberger KJ, Coletta RD, Schulte AP, et al. Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res 2005;65(7):2668-75
   Google Scholar
• Li CM, Guo M, Borczuk A, et al. Gene expression in Wilms’ tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 2002;160(6):2181-90
   PubMed Web of Science ®Google Scholar
• Robin TP, Smith A, McKinsey E, et al. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res 2012;10(8):1098-108
   Google Scholar
• Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365(9460):671-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang N, Huang J, et al. Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res 2005;65(3):925-32
   PubMed Web of Science ®Google Scholar
• Guo JT, Ding LH, Liang CY, et al. [Expression of EYA2 in non-small cell lang cancer]. Zhonghua Zhong Liu Za Zhi 2009;31(7):528-31
   Google Scholar
• Farabaugh SM, Micalizzi DS, Jedlicka P, et al. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 2012;31(5):552-62
   Google Scholar
• Zou H, Harrington JJ, Shire AM, et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev 2007;16(12):2686-96
   PubMed Web of Science ®Google Scholar
• Vincent A, Hong SM, Hu C, et al. Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget 2014;5(9):2575-87
   PubMedGoogle Scholar
• Gutierrez ML, Munoz-Bellvis L, Abad Mdel M, et al. Association between genetic subgroups of pancreatic ductal adenocarcinoma defined by high density 500 K SNP-arrays and tumor histopathology. PLoS One 2011;6(7):e22315
   Google Scholar
• Wang QF, Wu G, Mi S, et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011;117(25):6895-905
   PubMed Web of Science ®Google Scholar
• Clark SW, Fee BE, Cleveland JL. Misexpression of the eyes absent family triggers the apoptotic program. J Biol Chem 2002;277(5):3560-7
   Google Scholar
• Wu K, Li Z, Cai S, et al. EYA1 phosphatase function is essential to drive breast cancer cell proliferation through cyclin D1. Cancer Res 2013;73(14):4488-99
   Google Scholar
• Pandey RN, Rani R, Yeo EJ, et al. The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene 2010;29(25):3715-22
   Google Scholar
• Tadjuidje E, Wang TS, Pandey RN, et al. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone. PLoS One 2012;7(4):e34806
   PubMed Web of Science ®Google Scholar
• Auvergne RM, Sim FJ, Wang S, et al. Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep 2013;3(6):2127-41
   PubMed Web of Science ®Google Scholar
• Yan C, Higgins PJ. Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta 2013;1835(1):76-85
   Google Scholar
• Wu W, Ren Z, Li P, et al. Six1: A critical transcription factor in tumorigenesis. Int J Cancer 2014. [Epub ahead of print]
   Google Scholar
• Nero TL, Morton CJ, Holien JK, et al. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer 2014;14(4):248-62
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Garon EB, et al. Phase II study of singsle-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012;18(11):3163-9
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68(9):3421-8
   PubMed Web of Science ®Google Scholar
• Ding Q, Zhang Z, Liu JJ, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 2013;56(14):5979-83
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012;13(11):1133-40
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
   PubMed Web of Science ®Google Scholar
• Carry JC, Garcia-Echeverria C. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic. Bioorg Med Chem Lett 2013;23(9):2480-5
   PubMed Web of Science ®Google Scholar
• Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 1995;267(5196):383-6
   PubMed Web of Science ®Google Scholar
• Grifone R, Laclef C, Spitz F, et al. Six1 and Eya1 expression can reprogram adult muscle from the slow-twitch phenotype into the fast-twitch phenotype. Mol Cell Biol 2004;24(14):6253-67
   PubMedGoogle Scholar
• Gordon BS, Delgado Diaz DC, White JP, et al. Six1 and Six1 cofactor expression is altered during early skeletal muscle overload in mice. J Physiol Sci 2012;62(5):393-401
   Google Scholar
• Le Grand F, Grifone R, Mourikis P, et al. Six1 regulates stem cell repair potential and self-renewal during skeletal muscle regeneration. J Cell Biol 2012;198(5):815-32
   PubMed Web of Science ®Google Scholar
• Nord H, Nygard Skalman L, von Hofsten J. Six1 regulates proliferation of Pax7-positive muscle progenitors in zebrafish. J Cell Sci 2013;126(Pt 8):1868-80
   Google Scholar
• Liu Y, Chakroun I, Yang D, et al. Six1 regulates MyoD expression in adult muscle progenitor cells. PLoS One 2013;8(6):e67762
   Google Scholar
• Delgado-Olguin P, Huang Y, Li X, et al. Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet 2012;44(3):343-7
   Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12(5):489-95
   PubMed Web of Science ®Google Scholar
• Jung SK, Jeong DG, Chung SJ, et al. Crystal structure of ED-Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor. FASEB J 2010;24(2):560-9
   Google Scholar
• He R, Zeng LF, He Y, et al. Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J 2013;280(2):731-50
   PubMedGoogle Scholar
• Pandey RN, Wang TS, Tadjuidje E, et al. Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents. PLoS One 2013;8(12):e84582
   Google Scholar
• Park H, Jung SK, Yu KR, et al. Structure-based virtual screening approach to the discovery of novel inhibitors of eyes absent 2 phosphatase with various metal chelating moieties. Chem Biol Drug Des 2011;78(4):642-50
   Google Scholar
• Park H, Ryu SE, Kim SJ. Structure-based de novo design of Eya2 phosphatase inhibitors. J Mol Graph Model 2012;38:382-8
   Google Scholar
• Krueger AB, Dehdashti SJ, Southall N, et al. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity. J Biomol Screen 2013;18(1):85-96
   Google Scholar
• Krueger AB, Drasin DJ, Lea WA, et al. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated migration. J Biol Chem 2014;289(23):16349-61
   Google Scholar
• van Westen GJ, Gaulton A, Overington JP. Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput Biol 2014;10(4):e1003559
   PubMed Web of Science ®Google Scholar
• Darnell JEJr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2(10):740-9
   PubMed Web of Science ®Google Scholar
• Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006;6(4):307-20
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53(7):2719-40
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar